SCHEMBL29348902

SCHEMBL29348902

Brc1ccc(Cc2ncccn2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 2/20 0.40
▸ GRM2 Q14416 1/20 0.39
▸ MBOAT4 Q96T53 1/20 0.38
▸ HTT P42858 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ NPC1 O15118 3/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ PKM P14618 1/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ ADRA2A P08913 2/20 0.32
▸ ADRA2B P18089 2/20 0.32
▸ ADRA2C P18825 2/20 0.32
▸ PLAU P00749 1/20 0.32
▸ MAPT P10636 2/20 0.31
▸ KMT2A Q03164 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17663847 0.76 GBA1 (0.45) GBA1GRM2MBOAT4ALDH1A1KDM4E
SCHEMBL4318045 0.72 MBOAT4 (0.41) GBA1GRM2MBOAT4ALDH1A1KDM4E
SCHEMBL13171961 0.72 L3MBTL1 (0.53) ALDH1A1SMN1; SMN2HRH4HRH3MAPT
SCHEMBL507025 0.72 — —
SCHEMBL29348960 0.71 MBOAT4 (0.37) GBA1GRM2MBOAT4ALDH1A1KDM4E
SCHEMBL31637575 0.71 MBOAT4 (0.37) GBA1GRM2MBOAT4ALDH1A1KDM4E
SCHEMBL15334882 0.70 — —
SCHEMBL7551937 0.70 — —
SCHEMBL22703601 0.70 — —
SCHEMBL668445 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 — — EP disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
Send feedback